Full Press Release Details
Ultragenyx Announces Proposed Public Offering of Common Stock.
RARE
Ultragenyx Announces Proposed Public Offering of Common Stock
Key Takeaway: Ultragenyx Announces Proposed Public Offering of Common Stock
Price reaction · baseline $37.02 (2023-10-16 close) · hit after-hours · 2 other RARE headline(s) in the window, move may be shared
day 0 close
-0.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+43%
120-day peak, hindsight
Typical move
2.9%
average across 6 past catalysts
Cash runway
~13 mo
Low dilution risk
Lead asset
BPS804
Phase 2 · Hypophosphatasia